Piper Sandler analyst Matt O’Brien raised the firm’s price target on Sight Sciences to $6 from $5 and keeps a Neutral rating on the shares. The company reported Q1 results with sales that came in above expectations and were largely driven by surgical glaucoma, the analyst tells investors in a research note. The firm is encouraged by the nice start to the year but prefers to stay on the sidelines until Sight’s re-acceleration gains momentum.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Enhances Transparency with Strategic Financial Moves
- Sight Sciences announces $34M patent infringement verdict against Alcon
- Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
- Sight Sciences to Report First Quarter Financial Results on May 2, 2024
- Sight Sciences publishes results from MIGS study in AJO